Zhang Chen, Li Caoyi, Wu Long, Wang Yuan, Huang Ke, Yang Xu, Zhao Sai, Zhu Haoran, Shi Lin, Wang Jian
Department of General Surgery, The Second Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Internal Medicine-Cardiovascular Department, Jiangsu University Affiliated Hospital, Zhenjiang, Jiangsu, China.
Front Oncol. 2025 Apr 24;15:1538335. doi: 10.3389/fonc.2025.1538335. eCollection 2025.
This study aims to evaluate the expression of Smad ubiquitination regulatory factors (SMURFs) in pancreatic cancer and analyze their relationship with cancer staging and prognosis, and to investigate the potential of SMURF as a therapeutic target for pancreatic cancer.
A total of 179 patients with pancreatic cancer were identified in The Cancer Genome Atlas (TCGA) database. This dataset was utilized in the study to analyze the expression of SMURF1 and SMURF2 and their correlation with pancreatic cancer staging and patient survival. assays including CCK-8, EdU, colony formation, and wound-healing were employed to elucidate the function of SMURF1 in the proliferation and migration of pancreatic cancer cells.
High expression of SMURF1 showed a significant positive correlation with T staging, histological and pathological grades, as well as clinical treatment outcomes of pancreatic cancer (<0.050). Meanwhile, high expression of SMURF2 indicated a positive correlation with the histological grade of pancreatic cancer (<0.050). However, high expression of SMURF1 was negatively correlated with overall survival (OS) and progression-free interval (PFI) (<0.050). High expression of SMURF2 was negatively correlated with PFI (<0.050). Inhibition of SMURF1 expression suppressed the proliferation and migration of pancreatic cancer cells.
High expression of SMURF1 could potentially be a therapeutic target and a poor prognostic indicator in pancreatic cancer.
本研究旨在评估Smad泛素化调节因子（SMURFs）在胰腺癌中的表达，分析其与癌症分期及预后的关系，并探讨SMURF作为胰腺癌治疗靶点的潜力。
在癌症基因组图谱（TCGA）数据库中识别出179例胰腺癌患者。本研究使用该数据集分析SMURF1和SMURF2的表达及其与胰腺癌分期和患者生存的相关性。采用CCK-8、EdU、集落形成和伤口愈合等实验来阐明SMURF1在胰腺癌细胞增殖和迁移中的作用。
SMURF1的高表达与胰腺癌的T分期、组织学和病理学分级以及临床治疗结果呈显著正相关（<0.050）。同时，SMURF2的高表达与胰腺癌的组织学分级呈正相关（<0.050）。然而，SMURF1的高表达与总生存期（OS）和无进展生存期（PFI）呈负相关（<0.050）。SMURF2的高表达与PFI呈负相关（<0.050）。抑制SMURF1表达可抑制胰腺癌细胞的增殖和迁移。
SMURF1的高表达可能是胰腺癌的一个治疗靶点和不良预后指标。
